Beam Therapeutics Stock Analysis


USD 65.73  4.77  7.82%   

The new price hike of Beam Therapeutics could raise concerns from stakeholders as the firm is trading at a share price of 65.73 on 1,898,636 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.0. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Beam Therapeutics partners.
Continue to Trending Equities.
The Beam Therapeutics stock analysis report makes it easy to digest most publicly released information about Beam Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Beam Therapeutics Stock analysis module also helps to analyze the Beam Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Beam Therapeutics Stock Analysis Notes

About 82.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 3.59. Beam Therapeutics next dividend is scheduled to be issued on the February 4, 2014. The entity had 2:1 split on the October 26, 1990. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Beam Therapeutics please contact the company at 857 327-8775 or go to

Beam Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Beam Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Beam Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Beam Therapeutics is way too risky over 90 days horizon
Beam Therapeutics appears to be risky and price may revert if volatility continues
Beam Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 60.27 M. Net Loss for the year was (238.29 M) with loss before overhead, payroll, taxes, and interest of (180.29 M).
Beam Therapeutics has a frail financial position based on the latest SEC disclosures
Over 82.0% of the company shares are held by institutions such as insurance companies
Latest headline from Sector Update Health Care Stocks Lean Lower Premarket Monday - InvestorsObserver

Beam Therapeutics Upcoming and Recent Events

Earnings reports are used by Beam Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Beam Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report21st of March 2022
Next Financial Report10th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End21st of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Beam Therapeutics Largest EPS Surprises

Earnings surprises can significantly impact Beam Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Beam Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Beam Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Beam Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Beam Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
1st of August 2022
Financial Statements and Exhibits. Other Events
14th of July 2022
Unclassified Corporate Event
10th of June 2022
Submission of Matters to a Vote of Security Holders
9th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
28th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of February 2022
Unclassified Corporate Event
9th of February 2022
Unclassified Corporate Event
4th of February 2022
Unclassified Corporate Event

Beam Therapeutics Thematic Classifications

In addition to having Beam Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Beam Therapeutics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Beam Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Beam Therapeutics backward and forwards among themselves. Beam Therapeutics' institutional investor refers to the entity that pools money to purchase Beam Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ark Investment Management LlcCommon Shares8.8 M309.3 M
Sumitomo Mitsui Trust Holdings IncCommon Shares292 K11.3 M
Nikko Asset Management Americas IncCommon Shares292 K10.8 M
Mirae Asset Global Investments Co LtdCommon Shares213 K8.2 M
Capital Advisors IncCommon Shares108.7 K4.2 M
Russell Investments Group LtdCommon Shares90.2 K3.5 M
Candriam ScaCommon Shares79.7 K3.1 M
Simplex Trading LlcPut Options17.7 K685 K
Note, although Beam Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Beam Therapeutics Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.42 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Beam Therapeutics's market, we take the total number of its shares issued and multiply it by Beam Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Beam Therapeutics Profitablity

Beam Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Beam Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Beam Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Beam Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Beam Therapeutics' profitability requires more research than a typical breakdown of Beam Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(72.34) (78.05) 
Return on Average Assets(0.35) (0.38) 
Return on Average Equity(0.56) (0.57) 
Return on Invested Capital(0.55) (0.59) 
Return on Sales(7.15) (7.72) 

Management Efficiency

The entity has return on total asset (ROA) of (6.6) % which means that it has lost $6.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (38.08) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics management efficiency ratios could be used to measure how well beam therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to pull down to -78.05. The value of Return on Average Assets is estimated to pull down to -0.38. Beam Therapeutics Net Current Assets as percentage of Total Assets are relatively stable at the moment as compared to the past year. The company's current value of Net Current Assets as percentage of Total Assets is estimated at 77.54. Average Assets is expected to hike to about 1.1 B this year, although the value of Asset Turnover will most likely fall to 0.0438.
Last ReportedProjected for 2022
Book Value per Share 12.87  13.89 
Enterprise Value over EBIT(13.00) (14.03) 
Enterprise Value over EBITDA(13.62) (14.70) 
Price to Book Value 6.57  8.90 
Tangible Assets Book Value per Share 22.96  22.50 
Enterprise Value4.9 B5.4 B
Tangible Asset Value1.5 B1.6 B

Technical Drivers

As of the 10th of August, Beam Therapeutics shows the risk adjusted performance of 0.1975, and Mean Deviation of 4.77. Beam Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Beam Therapeutics, which can be compared to its rivals. Please confirm Beam Therapeutics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Beam Therapeutics is priced correctly, providing market reflects its regular price of 65.73 per share. Given that Beam Therapeutics has jensen alpha of 0.9778, we suggest you to validate Beam Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Beam Therapeutics Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Simple Moving Average indicator is calculated by adding the closing price of Beam Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Beam Therapeutics short-term fluctuations and highlight longer-term trends or cycles.

Beam Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Beam Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Beam Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Beam Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Beam Therapeutics Predictive Daily Indicators

Beam Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Beam Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Beam Therapeutics Forecast Models

Beam Therapeutics time-series forecasting models is one of many Beam Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Beam Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Beam Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Beam Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Beam Therapeutics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Beam Therapeutics. By using and applying Beam Therapeutics Stock analysis, traders can create a robust methodology for identifying Beam Therapeutics entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(6.30) (6.80) 
Gross Margin 0.90  0.89 
Profit Margin(6.43) (6.94) 
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Beam Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Equity Forecasting Now


Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module
Continue to Trending Equities. Note that the Beam Therapeutics information on this page should be used as a complementary analysis to other Beam Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Beam Therapeutics Stock analysis

When running Beam Therapeutics price analysis, check to measure Beam Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Beam Therapeutics is operating at the current time. Most of Beam Therapeutics' value examination focuses on studying past and present price action to predict the probability of Beam Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Beam Therapeutics' price. Additionally, you may evaluate how the addition of Beam Therapeutics to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Bond Directory
Find actively traded corporate debentures issued by US companies
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Valuation
Check real value of public entities based on technical and fundamental data
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Beam Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.5 B
Quarterly Revenue Growth YOY
1.4 K
Return On Assets
Return On Equity
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Beam Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.